How AstraZeneca Overcame US Anti-Trust Obstacles For Alexion Deal
CFO Confident Of Closing In Q3
While the sector is gripped by fears that overly zealous anti-competition regulators pose a threat to future M&A biopharma deals, AstraZeneca's acquisition of Alexion has sauntered through the US FTC's review. Its CFO Marc Dunoyer tells Scrip why the company is not surprised.
You may also be interested in...
Having completed its $39bn takeover of Alexion, AstraZeneca must now demonstrate its ability to maximize revenues and performance from the US rare disease specialist.
Antitrust authorities in the UK have followed their counterparts in the EU, Japan and the US to approve the AstraZeneca and Alexion link-up, the biggest pharma M&A deal of 2020.
Keeping Track: US FDA Clears Pfizer’s Prevnar 20; Dermavant Submits Tapinarof; Adamis Returns With Zimhi
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker